Product Information
VEMLIDY 25 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $51.9838 per EA under NDC 61958230101. Its NADAC has been published 490 times since May 17, 2017.
FDA first approved this application on Nov 10, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
25 mg/1
Manufacturer
Gilead Sciences, Inc.NDC
61958230101
Classification
Brand
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TENOFOVIR ALAFENAMIDE FUMARATEApproval Type
New Drug (NDA)
FDA Application
NDA208464FDA Approved
11/10/2016
TE Code
AB
On Market Since
11/10/2016
Pharmacological Classes
Price Statistics
The NADAC for VEMLIDY 25 MG TABLET has been published 490 times since May 17, 2017, and over the history we have for it it has risen 63.0%. The table below summarizes its recorded NADAC range and movement.
| Current price | $51.9838 per EA |
|---|---|
| All-time high | $51.9838 (Sep 30, 2026) |
| All-time low | $31.8880 (May 17, 2017) |
| 52-week high | $51.9838 |
| 52-week low | $49.0144 |
| Median price | $41.7796 |
| Average price | $41.2927 |
| Largest weekly change | +6.9% (Jan 10, 2018) |
| Weeks tracked | 490 |
| Tracking since | May 17, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the tenofovir alafenamide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Gilead Sciences, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
tenofovir alafenamide market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of VEMLIDY 25 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for VEMLIDY 25 MG TABLET, manufactured by Gilead Sciences, Inc., is $51.9838 per EA (NDC 61958230101), effective Sep 30, 2026.
How has the price of VEMLIDY 25 MG TABLET changed over time?
Over the history we have for it, the NADAC for VEMLIDY 25 MG TABLET has risen 63.0%. It has been tracked across 490 weekly CMS publications since May 17, 2017.
What are the highest and lowest recorded NADAC prices for VEMLIDY 25 MG TABLET?
Since May 17, 2017, the NADAC for VEMLIDY 25 MG TABLET has ranged from a low of $31.8880 (May 17, 2017) to a high of $51.9838 (Sep 30, 2026), with a median of $41.7796 per EA.
Are there cheaper alternatives to VEMLIDY 25 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of VEMLIDY 25 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures VEMLIDY 25 MG TABLET?
VEMLIDY 25 MG TABLET (NDC 61958230101) is labeled by Gilead Sciences, Inc., and CMS classifies it as a brand product.